Abivax SA (FR:ABVX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abivax, a clinical-stage biotech company, has disclosed its share capital and voting rights as of May 31, 2024, revealing a total of 62,930,818 shares and 69,950,376 theoretical voting rights. The company, known for developing treatments for chronic inflammatory diseases, reported 69,938,945 exercisable voting rights, excluding shares without voting rights.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.